BLS Pharmaceuticals Limited (ASX:BLS)

Market Cap	277.52M +211.7%
Revenue (ttm)	73.91M +152.4%
Net Income	15.40M +214.1%
EPS	0.07 +191.3%
Shares Out	230.30M
PE Ratio	17.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	401,103
Open	1.230
Previous Close	1.205
Day's Range	1.165 - 1.230
52-Week Range	0.330 - 1.295
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About BLS Pharmaceuticals

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BLS

Financial Performance

In fiscal year 2026, BLS Pharmaceuticals's revenue was 73.91 million, an increase of 152.42% compared to the previous year's 29.28 million. Earnings were 15.40 million, an increase of 214.15%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 22, 2026

Data Sources Report a data error